A focused review of hematopoietic neoplasms occurring in the therapy-related setting

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 3512-3523

  Zhang, Liping ^a   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Autoimmune disease; Myelodysplastic syndromes; Myelodysplastic myeloproliferative neoplasm; Myeloproliferative neoplasm; Radiation; Therapy related myeloid neoplasm

Indexed keywords

ADVERSE EFFECTS; HEMATOLOGIC NEOPLASMS; HUMAN; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; RADIOTHERAPY;

HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY;

EID: 84906257452     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Allan JM and Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005; 5: 943-955.
2. Seedhouse C and Russell N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol 2007; 137: 513-529.
3. Kern W, Haferlach T, Schnittger S, Hiddemann W and Schoch C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004; 22: 2510-2511.
4. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kundgen A, Gotze K, Rummel M, Nachbaur D, Schlegelberger B, Gohring G, Spath D, Morlok C, Zucknick M, Ganser A, Dohner H and Schlenk RF. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117: 2137-2145.
5. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD and Larson RA. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43-52.
6. Vardiman JW, Brunning RD, Larson RA, Matutes E, Baumann I, Thiele J. Therapy-related myeloid neoplasms. World Health Organization Classification of Tumours. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
7. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI and Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009; 100: 822-828.
8. Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O and Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011; 29: 2897-2903.
9. Braun T and Fenaux P. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? Best Pract Res Clin Haematol 2013; 26: 327-336.
10. Bernatsky S, Clarke AE and Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008; 168: 378-381.
11. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM and Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27: 250-255.
12. Coso D, Costello R, Cohen-Valensi R, Sainty D, Nezri M, Gastaut JA and Bouabdallah R. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy. Ann Oncol 1999; 10: 362-363.
13. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA and Schiffer CA. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002; 20: 3878-3884.
14. Zhou Y, Tang G, Medeiros LJ, McDonnell TJ, Keating MJ, Wierda WG and Wang SA. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 2012; 25: 237-245.
15. Bowcock SJ, Rassam SM, Lim Z, Ward SM, Ryali MM and Mufti GJ. High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders. Br J Haematol 2006; 134: 242-243.
16. Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH and Westerman D. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006; 91: 1546-1550.
17. Ramkumar B, Chadha MK, Barcos M, Sait SN, Heyman MR and Baer MR. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. Cancer Genet Cytogenet 2008; 182: 126-129.
18. Ammatuna E, Montesinos P, Hasan SK, Ramadan SM, Esteve J, Hubmann M, Pagoni M, Grimwade D, Sanz MA and Lo-Coco F. Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica 2011; 96: 621-625.
19. Hasan SK, Buttari F, Ottone T, Voso MT, Hohaus S, Marasco E, Mantovani V, Garagnani P, Sanz MA, Cicconi L, Bernardi G, Centonze D and Lo-Coco F. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. Neurology 2011; 76: 1059-1065.
20. Diak P, Siegel J, La Grenade L, Choi L, Lemery S and McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62: 2517-2524.
21. Ramenghi U, Bonissoni S, Migliaretti G, DeFranco S, Bottarel F, Gambaruto C, DiFranco D, Priori R, Conti F, Dianzani I, Valesini G, Merletti F and Dianzani U. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood 2000; 95: 3176-3182.
22. DiNardo CD, Ogdie A, Hexner EO, Frey NV, Loren AW and Luger SM. Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease. Leuk Lymphoma 2013; 54: 1235-1241.
23. Cronkite EP, Moloney W and Bond VP. Radiation leukemogenesis: an analysis of the problem. Am J Med 1960; 28: 673-682.
24. Mole RH. The development of leukaemia in irradiated animals. Br Med Bull 1958; 14: 174-177.
25. Abdelhameed A, Pond GR, Mitsakakis N, Brandwein J, Chun K, Gupta V, Kamel-Reid S, Lipton JH, Minden MD, Schimmer A, Schuh A, Yee K and Messner HA. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that in clude chemotherapy and/or radiation. Cancer 2008; 112: 1513-1521.
26. Bhide SA and Nutting CM. Recent advances in radiotherapy. BMC Med 2010; 8: 25.
27. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M and De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008; 9: 367-375.
28. Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA and Hasserjian RP. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2340-2347.
29. Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH, Patel K, Medeiros LJ, Garcia-Manero G and Wang SA. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 2014; 28: 185-189.
30. Focosi D, Galimberti S and Petrini M. Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases. Haematologica 2007; 92: e96-97.
31. Grudeva-Popova J, Yaneva M, Zisov K and Ananoshtev N. Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review. J BUON 2007; 12: 129-132.
32. Schroeder T, Kuendgen A, Kayser S, Kroger N, Braulke F, Platzbecker U, Klarner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G and Germing U. Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica 2012; 97: 206-212.
33. Larson RA. Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2300-2302.
34. Bacher U, Haferlach C, Alpermann T, Schnittger S, Kern W and Haferlach T. Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma 2013; 54: 639-642.
35. Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, Philip P, Diaz MO and Rowley JD. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993; 82: 3705-3711.
36. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975-1986.
37. Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, Nimer SD, Levine RL and Klimek VM. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 2013; 98: 908-912.
38. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D and Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
39. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O and Levine RL. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
40. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J, Wlodarski MW, Kolking B, Wichmann M, Gorlich K, Gohring G, Bug G, Ottmann O, Niemeyer CM, Hofmann WK, Schlegelberger B, Ganser A and Heuser M. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
41. Pedersen-Bjergaard J, Andersen MK, Andersen MT and Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008; 22: 240-248.
42. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, Guerci A, Gratecos N, Rayon C, San Miguel J, Odriozola J, Cahn JY, Huguet F, Vekhof A, Stamatoulas A, Dombret H, Capote F, Esteve J, Stoppa AM and Fenaux P. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2123-2137.
43. Yin CC, Glassman AB, Lin P, Valbuena JR, Jones D, Luthra R and Medeiros LJ. Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol 2005; 123: 840-848.
44. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Ades L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NC, Cho mienne C, Solomon E, Fenaux P and Grimwade D. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352: 1529-1538.
45. Hoffmann L, Moller P, Pedersen-Bjergaard J, Waage A, Pedersen M and Hirsch FR. Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. Ann Oncol 1995; 6: 781-788.
46. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC and Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33: 395-400.
47. Ottone T, Hasan SK, Voso MT, Ledda A, Montefusco E, Fenu S, Pagoni M, Hubmann M, Lunghi M, Platzbecker U and Lo-Coco F. Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders. Am J Hematol 2014; 89: 346-347.
48. Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370-2379.
49. Slovak ML, Bedell V, Popplewell L, Arber DA, Schoch C and Slater R. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer 2002; 33: 379-394.
50. Arber DA, Slovak ML, Popplewell L, Bedell V, Ikle D and Rowley JD. Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations. Am J Clin Pathol 2002; 117: 306-313.
51. Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R, Medeiros LJ and Wang SA. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 2009; 131: 647-655.
52. Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T and Schnittger S. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia 2014; 28: 1449-58.
53. Schnittger S, Bacher U, Haferlach C, Kern W and Haferlach T. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients. Leukemia 2007; 21: 725-731.
54. Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Spath D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Kohne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Gotze K, Horst HA, Ringhoffer M, Lubbert M, Wattad M, Salih HR, Kundgen A, Dohner H and Dohner K. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 2013; 121: 170-177.
55. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ and Heinrich MC. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005; 19: 1536-1542.
56. Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W, Schnittger S and Haferlach T. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010; 24: 1065-1069.
57. Larson RA and Le Beau MM. Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm. Mediterr J Hematol Infect Dis 2011; 3: e2011032.
58. Churpek JE and Larson RA. The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol 2013; 26: 309-317.
59. Ahmed F, Osman N, Lucas F, Neff G, Smolarek T, Bennett JM and Komrokji RS. Therapy related CMML: a case report and review of the literature. Int J Hematol 2009; 89: 699-703.
60. Kim KB, Faderl S, Hwang CS and Khuri FR. Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature. J Clin Pharm Ther 2006; 31: 401-406.
61. Knipp S, Hildebrandt B, Richter J, Haas R, Germing U and Gattermann N. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 2005; 90: 691-693.
62. Muroi K, Miyata T, Saito M, Hatake K, Amemiya Y and Miura Y. Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14). Acta Haematol 1996; 96: 251-254.
63. Oo TH and Kenney L. Therapy-related chronic myelomonocytic leukemia with unique chromosomal abnormalities: monosomy 7 and t(12;17)(p13;q11.2). Am J Hematol 2007; 82: 248-249.
64. Satake N, Ishida Y, Otoh Y, Hinohara S, Kobayashi H, Sakashita A, Maseki N and Kaneko Y. Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation. Genes Chromosomes Cancer 1997; 20: 60-63.
65. Ueki K, Sato S, Tamura J, Sawamura M, Murakami H, Naruse T and Tsuchiya J. Three cases of multiple myeloma developing into melphalan-related chronic myelomonocytic leuke- mia. J Med 1991; 22: 157-161.
66. Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, Larson RA and Vardiman JW. Therapy-related myelodysplastic syndro- me: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007; 127: 197-205.
67. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H and Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 2013; 122: 2807-2811; quiz 2920.
68. Takeshita A, Naito K, Shinjo K, Sahara N, Matsui H, Ohnishi K, Beppu H, Ohtsubo K, Horii T, Maekawa M, Inaba T and Ohno R. Deletion 6p23 and add(11)(p15) leading to NUP98 translocation in a case of therapy-related atypical chronic myelocytic leukemia transforming to acute myelocytic leukemia. Cancer Genet Cytogenet 2004; 152: 56-60.
69. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R and Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123: 2645-2651.
70. Pedersen-Bjergaard J. Acute lymphoid leukemia with t(4;11)(q21;q23) following chemotherapy with cytostatic agents targeting at DNA-topoisomerase II. Leuk Res 1992; 16: 733-735.
71. Pagano L, Pulsoni A, Tosti ME, Annino L, Mele A, Camera A, Martino B, Guglielmi C, Cerri R, Di Bona E, Invernizzi R, Castagnola C, Bassan R, Mele L, Todeschini G, Leone G and Mandelli F. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol 1999; 106: 1037-1040.
72. Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G and Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol 2001; 114: 539-543.
73. Ishizawa S, Slovak ML, Popplewell L, Bedell V, Wrede JE, Carter NH, Snyder DS and Arber DA. High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities. Leukemia 2003; 17: 1091-1095.
74. Racke F, Cole C, Walker A, Jones J and Heerema NA. Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification. Cancer Genet 2012; 205: 653-656.
75. Tang G, Zuo Z, Thomas DA, Lin P, Liu D, Hu Y, Kantarjian HM, Bueso-Ramos C, Medeiros LJ and Wang SA. Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica 2012; 97: 919-925.
76. Thandla S, Alashari M, Green DM and Aplan PD. Therapy-related T cell lymphoblastic lymphoma with t(11;19)(q23;p13) and MLL gene rearrangement. Leukemia 1999; 13: 2116-2118.
77. Bee PC, Gan GG, Sangkar JV, Teh A and Goh KY. A case of T-cell acute lymphoblastic leukemia after treatment of acute promyelocytic leukemia. Int J Hematol 2004; 79: 358-360.
78. Liso V, Specchia G, Pannunzio A, Mestice A, Palumbo G and Biondi A. T-cell acute lymphoblastic leukemia occurring in a patient with acute promyelocytic leukemia. Haematologica 1998; 83: 471-473.
79. Tsuboi K, Komatsu H, Miwa H, Iida S, Banno S, Wakita A, Nitta M and Ueda R. T-cell acute lymphoblastic leukemia as a secondary leukemia after a 3-year remission of acute myelocytic leukemia. Int J Hematol 2003; 77: 518-521.
80. Schnatter AR, Glass DC, Tang G, Irons RD and Rushton L. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst 2012; 104: 1724-1737.
81. Fu B, Ok CY, Goswami M, Xei W, Jaso JM, Muzzafar T, Bueso-Ramos C, Verstovsek S, Garcia-Manero G, Medeiros LJ and Wang SA. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol 2013; 92: 1335-1343.
82. Fu B, Jaso JM, Sargent RL, Goswami M, Verstovsek S, Medeiros LJ and Wang SA. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol 2014; 27: 681-689.